Developer docs
API playgroundTry for free, no card

Search company profiles

Mindset Pharma

Full company profile

uuid0002s35

Namestring
Mindset Pharma
Legal namestring
Mindset Pharma, Inc.
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Mindset Pharma was a Toronto, Canada-based drug discovery and R&D company that developed novel serotonin 5-HT2A receptor agonists — a new class of compounds being investigated as potential therapies for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The firm's underlying technology centered on proprietary synthesis processes for next-generation psychedelic-inspired small molecules targeting the 5-HT2A receptor, with intellectual property protections around both the compounds and their manufacturing routes. Mindset positioned itself within the broader psychiatric and neurological disorders therapeutic area, addressing indications with explicitly high unmet medical need.

The company's business model was pre-commercial and pre-revenue. With a headcount of 1-10 employees, Mindset operated as a discovery-stage biotech funded by equity capital — most recently a December 2020 financing of approximately $4.17 million — and monetized through licensing/royalty pathways that had not yet materialized prior to the acquisition. The go-to-market motion was partnership-driven rather than sales-driven: the company's primary commercial relationship was a January 2022 joint development agreement with The McQuade Center for Strategic Research and Development (MSRD), an affiliate of Otsuka Pharmaceutical, to co-develop 5-HT2A agonists for TRD and PTSD.

In September 2023, Otsuka Pharmaceutical (via Otsuka America Pharmaceutical, Inc., 'OAI') announced an all-cash acquisition of Mindset Pharma, executed through a Canadian Plan of Arrangement. The transaction closed in Q4 2023, making Mindset a wholly-owned subsidiary of OAI. Following the deal, Otsuka indicated it would continue developing multiple new 5-HT2A agonists across North America and Europe as part of its stated priority focus on psychiatry and neurology.

Short descriptiontext

Mindset Pharma was a Toronto-based drug discovery company developing proprietary serotonin 5-HT2A receptor agonists for treatment-resistant depression and PTSD, acquired by Otsuka Pharmaceutical in Q4 2023.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
psychedelic drug discovery, 5-HT2A receptor agonists, central nervous system therapeutics, treatment-resistant depression, psychiatric drug development
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Psychiatric Drug Discovery
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-Revenue R&D Stage
TypeLicensing Royalties
Description

Mindset Pharma was a drug discovery-based research and development company focused on developing novel therapeutic compounds. The company had not yet commercialized products and was operating through funding and partnership arrangements prior to its acquisition by Otsuka Pharmaceutical in September 2023.

otsuka-us.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Mindset Pharma is a drug discovery-based research and development company focused on developing next-generation therapeutics for psychiatric and neurological disorders. Its primary pipeline consists of novel serotonin 5-HT2A receptor agonists being developed as potential therapies for treatment-resistant depression and post-traumatic stress disorder (PTSD). The company operated through joint development agreements and strategic partnerships, most notably with Otsuka's affiliate MSRD, before being acquired by Otsuka Pharmaceutical in 2023.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Expected major innovation in psychiatric and neurological disorders field
Product overview1 text field

Mindset Pharma is a drug discovery-based research and development company focused on developing next generation therapeutics for psychiatric and neurological disorders. The company's primary pipeline is centered on 5-HT2A agonists—a new class of compounds targeting the serotonin 5-HT2A receptor. The lead compound is being developed for treatment-resistant depression and PTSD. In September 2023, Otsuka Pharmaceutical announced plans to acquire Mindset Pharma to strengthen its psychiatric and neurological pipeline.

Product and service1 record
15-HT2A Agonist Program
CategoryDrug Candidate / CNS Therapeutics
Description

A serotonin 5-HT2A receptor agonist drug candidate being developed as a potential therapy for treatment-resistant depression and post-traumatic stress disorder (PTSD). It represents a novel class of agonists for psychiatric and neurological disorders with high unmet medical needs and is intended for development and commercialization by a pharmaceutical partner (Otsuka Pharmaceutical post-acquisition) in North America and Europe.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1The McQuade Center for Strategic Research and Development, LLC (MSRD)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

In January 2022, Mindset and The McQuade Center for Strategic Research and Development, LLC (MSRD), an affiliate of Otsuka that invests in early-stage research programs, entered into a joint development agreement to support Mindset's research and develop a new class of agonists that activate the serotonin 5-HT2A receptor. The collaboration focused on developing compounds for treatment-resistant depression and PTSD.

otsuka-us.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage psychedelic medicine company developing intranasal 5-MeO-DMT and other serotonergic compounds for neuropsychiatric indications. Emerging competitor in the psychedelic CNS space.

TypeDirect peer
Description

Clinical-stage psychedelic medicine company developing psilocybin therapy for treatment-resistant depression. Directly comparable as a psychedelic-derived CNS drug developer targeting the same TRD indication.

TypeBroad incumbent
Description

Global pharmaceutical company and Mindset's acquirer, with designated priority therapeutic areas in psychiatry and neurology including aripiprazole and brexpiprazole. Now the parent of Mindset's pipeline.

TypeDirect peer
Description

CNS-focused biopharma developing innovative therapeutics for depression, including NMDA and GABA-modulating approaches. Comparable as a focused CNS drug discovery company targeting TRD and related indications.

TypeBroad incumbent
Description

Global CNS-focused pharmaceutical company partnered with Otsuka on brexpiprazole PTSD trials. Broad incumbent in psychiatry and neurology with overlapping strategic interests in TRD and PTSD.

TypeDirect peer
Description

Psychedelic drug discovery company developing deuterated tryptamine derivatives targeting 5-HT2A receptors for depression and anxiety disorders. Direct competitor in next-gen psychedelic CNS chemistry.

TypeDirect peer
Description

Clinical-stage company developing mebufotenin (5-MeO-DMT) and other 5-HT2A agonists for treatment-resistant depression. Targets the same receptor pathway and patient population as Mindset.

8MindMed
TypeDirect peer
Description

Psychedelic-inspired CNS drug developer with programs in LSD-derived and other serotonin receptor-targeting compounds for anxiety, depression, and ADHD. Closely aligned with Mindset's 5-HT2A agonist approach.

9ATAI Life Sciences
TypeDirect peer
Description

Clinical-stage biopharma platform company developing psychedelic and non-psychedelic compounds for mental health, including depression and PTSD. Operates a portfolio model similar to how Mindset was structured before acquisition.

TypeEmerging player
Description

Preclinical biotech developing non-hallucinogenic psychoplastogens that modulate 5-HT2A receptors for depression and other CNS indications. Comparable as a next-generation 5-HT2A-focused CNS drug discovery company.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mindset Pharma

Psychiatric Drug Discoverymindsetpharma.com

Mindset Pharma was a Toronto-based drug discovery company developing proprietary serotonin 5-HT2A receptor agonists for treatment-resistant depression and PTSD, acquired by Otsuka Pharmaceutical in Q4 2023.

What Mindset Pharma does

Mindset Pharma was a Toronto, Canada-based drug discovery and R&D company that developed novel serotonin 5-HT2A receptor agonists — a new class of compounds being investigated as potential therapies for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The firm's underlying technology centered on proprietary synthesis processes for next-generation psychedelic-inspired small molecules targeting the 5-HT2A receptor, with intellectual property protections around both the compounds and their manufacturing routes. Mindset positioned itself within the broader psychiatric and neurological disorders therapeutic area, addressing indications with explicitly high unmet medical need.

The company's business model was pre-commercial and pre-revenue. With a headcount of 1-10 employees, Mindset operated as a discovery-stage biotech funded by equity capital — most recently a December 2020 financing of approximately $4.17 million — and monetized through licensing/royalty pathways that had not yet materialized prior to the acquisition. The go-to-market motion was partnership-driven rather than sales-driven: the company's primary commercial relationship was a January 2022 joint development agreement with The McQuade Center for Strategic Research and Development (MSRD), an affiliate of Otsuka Pharmaceutical, to co-develop 5-HT2A agonists for TRD and PTSD.

In September 2023, Otsuka Pharmaceutical (via Otsuka America Pharmaceutical, Inc., 'OAI') announced an all-cash acquisition of Mindset Pharma, executed through a Canadian Plan of Arrangement. The transaction closed in Q4 2023, making Mindset a wholly-owned subsidiary of OAI. Following the deal, Otsuka indicated it would continue developing multiple new 5-HT2A agonists across North America and Europe as part of its stated priority focus on psychiatry and neurology.

Mindset Pharma firmographics

Firmographics
Name
Mindset Pharma
Legal name
Mindset Pharma, Inc.
Website
https://mindsetpharma.com
Company type
Private
Founded year
2011
Operating status
Acquired
Headcount range
1–10 employees
Short description
Mindset Pharma was a Toronto-based drug discovery company developing proprietary serotonin 5-HT2A receptor agonists for treatment-resistant depression and PTSD, acquired by Otsuka Pharmaceutical in Q4 2023.
Ownership category
akta.pro rank

Mindset Pharma industry classification

Industry
Product category
Psychiatric Drug Discovery
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Psychedelic drug discovery
  • 5-HT2A receptor agonists
  • Central nervous system therapeutics
  • Treatment-resistant depression
  • Psychiatric drug development

Where Mindset Pharma is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Markets served

Mindset Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Pre-Revenue R&D Stage: Mindset Pharma was a drug discovery-based research and development company focused on developing novel therapeutic compounds. The company had not yet commercialized products and was operating through funding and partnership arrangements prior to its acquisition by Otsuka Pharmaceutical in September 2023.

Go-to-market motion1 record

Marketing channels2 records

Mindset Pharma product offering

Product offering

Core offering

Mindset Pharma is a drug discovery-based research and development company focused on developing next-generation therapeutics for psychiatric and neurological disorders. Its primary pipeline consists of novel serotonin 5-HT2A receptor agonists being developed as potential therapies for treatment-resistant depression and post-traumatic stress disorder (PTSD). The company operated through joint development agreements and strategic partnerships, most notably with Otsuka's affiliate MSRD, before being acquired by Otsuka Pharmaceutical in 2023.

Product overview

Mindset Pharma is a drug discovery-based research and development company focused on developing next generation therapeutics for psychiatric and neurological disorders. The company's primary pipeline is centered on 5-HT2A agonists—a new class of compounds targeting the serotonin 5-HT2A receptor. The lead compound is being developed for treatment-resistant depression and PTSD. In September 2023, Otsuka Pharmaceutical announced plans to acquire Mindset Pharma to strengthen its psychiatric and neurological pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • 5-HT2A Agonist Program A serotonin 5-HT2A receptor agonist drug candidate being developed as a potential therapy for treatment-resistant depression and post-traumatic stress disorder (PTSD). It represents a novel class of agonists for psychiatric and neurological disorders with high unmet medical needs and is intended for development and commercialization by a pharmaceutical partner (Otsuka Pharmaceutical post-acquisition) in North America and Europe.

Quantifiable outcome

  • Expected major innovation in psychiatric and neurological disorders field

Companies that use Mindset Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Mindset Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Mindset Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • The McQuade Center for Strategic Research and Development, LLC (MSRD)coreStrategic or Co-development Partner · 1 January 2022In January 2022, Mindset and The McQuade Center for Strategic Research and Development, LLC (MSRD), an affiliate of Otsuka that invests in early-stage research programs, entered into a joint development agreement to support Mindset's research and develop a new class of agonists that activate the serotonin 5-HT2A receptor. The collaboration focused on developing compounds for treatment-resistant depression and PTSD.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Mindset Pharma competitors and assessment

Company assessment

Emerging players

  • Beckley Psytech: Clinical-stage psychedelic medicine company developing intranasal 5-MeO-DMT and other serotonergic compounds for neuropsychiatric indications. Emerging competitor in the psychedelic CNS space.
  • Delix Therapeutics: Preclinical biotech developing non-hallucinogenic psychoplastogens that modulate 5-HT2A receptors for depression and other CNS indications. Comparable as a next-generation 5-HT2A-focused CNS drug discovery company.

Direct peers

  • Compass Pathways: Clinical-stage psychedelic medicine company developing psilocybin therapy for treatment-resistant depression. Directly comparable as a psychedelic-derived CNS drug developer targeting the same TRD indication.
  • Sage Therapeutics: CNS-focused biopharma developing innovative therapeutics for depression, including NMDA and GABA-modulating approaches. Comparable as a focused CNS drug discovery company targeting TRD and related indications.
  • Cybin Inc: Psychedelic drug discovery company developing deuterated tryptamine derivatives targeting 5-HT2A receptors for depression and anxiety disorders. Direct competitor in next-gen psychedelic CNS chemistry.
  • GH Research: Clinical-stage company developing mebufotenin (5-MeO-DMT) and other 5-HT2A agonists for treatment-resistant depression. Targets the same receptor pathway and patient population as Mindset.
  • MindMed: Psychedelic-inspired CNS drug developer with programs in LSD-derived and other serotonin receptor-targeting compounds for anxiety, depression, and ADHD. Closely aligned with Mindset's 5-HT2A agonist approach.
  • ATAI Life Sciences: Clinical-stage biopharma platform company developing psychedelic and non-psychedelic compounds for mental health, including depression and PTSD. Operates a portfolio model similar to how Mindset was structured before acquisition.

Broad incumbents

  • Otsuka Pharmaceutical: Global pharmaceutical company and Mindset's acquirer, with designated priority therapeutic areas in psychiatry and neurology including aripiprazole and brexpiprazole. Now the parent of Mindset's pipeline.
  • Lundbeck: Global CNS-focused pharmaceutical company partnered with Otsuka on brexpiprazole PTSD trials. Broad incumbent in psychiatry and neurology with overlapping strategic interests in TRD and PTSD.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Customer concentration

Mindset Pharma social profiles

Digital presence

Mindset Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mindset Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Mindset Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mindset Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mindset Pharma

What does Mindset Pharma do?

Mindset Pharma is a drug discovery-based research and development company focused on developing next-generation therapeutics for psychiatric and neurological disorders. Its primary pipeline consists of novel serotonin 5-HT2A receptor agonists being developed as potential therapies for treatment-resistant depression and post-traumatic stress disorder (PTSD). The company operated through joint development agreements and strategic partnerships, most notably with Otsuka's affiliate MSRD, before being acquired by Otsuka Pharmaceutical in 2023.

Is Mindset Pharma a public or private company?

Mindset Pharma is a private company. It is classified as corporate owned and is currently acquired.

When was Mindset Pharma founded?

Mindset Pharma was founded in 2011. It employs 1 to 10 people.

Where is Mindset Pharma based?

Mindset Pharma is headquartered in Toronto, Canada, in the North America region.

How does Mindset Pharma make money?

One revenue line is on record: pre-Revenue R&D Stage.

Who are Mindset Pharma's main competitors?

Emerging players on record are Beckley Psytech and Delix Therapeutics. Direct peers are Compass Pathways, Sage Therapeutics, Cybin Inc, GH Research, MindMed and ATAI Life Sciences. Broad incumbents are Otsuka Pharmaceutical and Lundbeck.

Does Mindset Pharma have an API?

No public API is recorded for Mindset Pharma.

What industry is Mindset Pharma in?

Mindset Pharma's product category is Psychiatric Drug Discovery. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Markets DailyComparing CRISPR Therapeutics (NASDAQ:CRSP) & Mindset Pharma (OTCMKTS:MSSTF)This article presents a comparative investment analysis between CRISPR Therapeutics and Mindset Pharma across ten factors including analyst ratings, institutional ownership, profitability, valuation, and earnings. CRISPR Therapeutics emerges ahead in seven of the ten comparison categories, with a consensus price target of $68.06 implying 27.16% upside potential and a rating score of 2.58 versus zero for Mindset Pharma. CRISPR Therapeutics, a gene-editing company headquartered in Switzerland with U.S. and U.K. operations, trades at a price/sales ratio of 1,474.32 with negative net margins of -3,368.72% and net income of -$581.60 million, while Mindset Pharma, a psychedelic medicine developer based in Toronto, Canada, shows no revenue or profitability metrics available.MarketScreenerOtsuka America, Inc. completed the acquisition of Mindset Pharma Inc..Otsuka America, Inc. completed the acquisition of Mindset Pharma Inc. on October 27, 2023, following regulatory approvals and shareholder consent. The transaction, valued at CAD 75.9 million, results in the delisting of Mindset Pharma shares from major exchanges as it becomes part of Otsuka's portfolio.Otsuka USOtsuka Pharmaceutical to Acquire Mindset Pharma - Strengthens pipeline in the area of psychiatric and neurological disordersOtsuka Pharmaceutical has agreed to acquire Mindset Pharma in an all-cash transaction to strengthen its pipeline for psychiatric and neurological disorders. The acquisition involves the development of novel 5-HT 2A agonists targeting treatment-resistant depression and PTSD, with completion expected in the fourth quarter of 2023 following regulatory and shareholder approvals.YahooOtsuka Pharmaceutical to Acquire Mindset PharmaOtsuka Pharmaceutical Co., Ltd. has entered into a definitive agreement to acquire Mindset Pharma Inc. for approximately CAD $80 million in an all-cash transaction. Under the terms, Mindset shareholders will receive $0.75 per share, representing premiums of up to 51.5% based on recent trading averages. The acquisition aligns with Otsuka's strategic priority in psychiatry and neurology, aiming to integrate Mindset's novel compounds for treating neuropsychiatric disorders.BioSpaceMindset Pharma Provides Strategic Intellectual Property License to CybinMindset Pharma announced an exclusive licensing agreement with Cybin for a subset of its preclinical compounds, excluding its lead candidate MSP-1014. The deal includes an initial $500,000 payment and clinical development milestones up to $9,500,000, plus a 2% sales royalty.ForbesAfter Its Vilification In The 1960s, There Is Now A Renaissance In Psychedelic Drugs To Help Treat Depression And Mental Health IssuesPsychedelic drugs are being re-evaluated for treating depression and PTSD, with psilocybin and MDMA showing promise in clinical trials. Mindset Pharma is developing next-generation psychedelic medicines, and Oregon legalized psilocybin in 2020. The article notes a growing demand for new treatments amid the pandemic's mental health crisis.trib.alBig Pharma In Psychedelics: Inside Mindset Pharma’s Deal With OtsukaMindset Pharma announced a collaboration with Otsuka Pharmaceutical's McQuade Center, receiving a $5 million upfront payment. Otsuka will fully fund development of two short-acting psychedelic drug families, with non-dilutive funding for Phase 1 not capped. The partnership aims to advance next-generation psilocybin and DMT-inspired compounds.Business Wire BlogThe McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic MedicinesThe McQuade Center for Strategic Research and Development (MSRD), a member of the Otsuka family, announced a collaboration with Mindset Pharma to support the development of psychedelic medicines. MSRD made a $5 million upfront strategic investment to fund Phase 1a and 1b clinical trials for two families of Mindset's novel compounds targeting neurological and psychiatric disorders. The agreement includes rights of first refusal and negotiation for MSRD regarding future asset sales or mergers involving these specific drugs.GlobeNewswireMindset Pharma Announces Promising Test Results of its Novel and Proprietary Psilocybin-Inspired CompoundsMindset Pharma announced preliminary screening results of its patent-pending psilocybin-inspired compounds, which act as strongly on the 5HT-2A receptor as psilocin. Some compounds showed several-fold increases in efficacy and potency, validating the company's drug design. The company plans to move forward to in vivo testing.GlobeNewswireMindset Pharma Announces Filing of Groundbreaking Psilocybin Synthesis PatentMindset Pharma filed a provisional patent application with the USPTO for a process to synthesize psilocybin and psilocin. The company claims the process offers lower cost, milder conditions, and suitability for multi-kilogram scale manufacturing. The filing is a milestone toward building intellectual property for the medical psychedelic market.